Market Overview

UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress

Share:
Related
Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold
Mid-Afternoon Market Update: Crude Oil Up 2.5%; Xencor Shares Surge Following Deal With Novartis

Wedbush Securities initiated coverage on Regulus Therapeutics (NASDAQ: RGLS) with an Outperform rating and a $10 price target.

Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states. Oligonucleotide drug discovery and development is rapid and predictable as drugs are assembled using the complementary microRNA target as a template, and other oligonucleotide drugs inform ADME, pK, safety and tolerability."

Regulus Therapeutics closed at $4.34 on Wednesday.

Latest Ratings for RGLS

DateFirmActionFromTo
Jun 2016BMO CapitalDowngradesOutperformMarket Perform
Jun 2016Chardan CapitalMaintainsBuy
Apr 2016Chardan CapitalInitiates Coverage onBuy

View More Analyst Ratings for RGLS
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (RGLS)

View Comments and Join the Discussion!